May 31, 2007 by Brian LawlerBradley Offers to Buy ItselfBradley's CEO wants to take the company private.
May 31, 2007 by Brian LawlerBad Alkermes?Alkermes releases financial results and includes a little negative surprise for investors.
May 29, 2007 by Brian LawlerAmgen Is VexedThe European Union medical authority says nein to Amgen's cancer compound.
May 29, 2007 by Brian LawlerThe One Development-Stage Drug Stock to Own NowOne undervalued drug developer may be on the cusp of greatness.
May 29, 2007 by Brian LawlerNektar Squeezes ItselfNektar Therapeutics cuts costs after a slower rollout of its lead compound.
May 29, 2007 by Brian LawlerOne Final Look at the Old MylanMylan releases its fourth-quarter financial results.
May 25, 2007 by Brian LawlerBioMarin Waits for Another DrugBioMarin files a marketing application for its lead compound in development.
May 25, 2007 by Brian LawlerThe New, Slimmer CVTCV Therapeutics announces a new plan to reduce costs.
May 25, 2007 by Brian LawlerExelixis Must Pay Good OvertimeExelixis stays busy bringing new drugs into the clinic.
May 25, 2007 by Brian LawlerBristol-Myers Tries to Boost AbilifyBristol-Myers announces new data for one of its top compounds.
May 24, 2007 by Brian LawlerLearn From Northfield's Bloody ResultsNorthfield announces clinical trial results that investors can learn from.
May 22, 2007 by Brian LawlerElan Plunges AheadElan decides to push a key drug candidate into late-stage clinical testing.
May 22, 2007 by Brian LawlerPDL Announces More DataPDL announces new clinical trial data for its lead compound.
May 21, 2007 by Brian LawlerDUSA's Orphan Isn't UniqueDusa gets "orphan drug" status for its lead compound.
May 18, 2007 by Brian LawlerListen to Buffett: Invest in BiotechWarren Buffett has some sage advice that investors should listen to.
May 17, 2007 by Brian LawlerMedImmune Gets the Thumbs-UpAn advisory panel recommends expanded use for one of MedImmune's drugs.
May 17, 2007 by Brian LawlerAffymax on the AttackAffymax announces its first-quarter financial results.
